Icosavax
Public CompanyIcosavax develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19. Its platform uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Vaccines, Life Sciences
- Status
- Public Company
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
Founders
-
Neil King Co-founder